Sunday 18 October 2026
Export PFSA’s income statement to Excel — free account
PROFUSA, Inc.
PFSA Healthcare Medical Devices
PROFUSA, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $100,000.00. In the quarter to June 2026, EPS grew 98.3%, free cash flow fell 359.3% and total debt fell 89.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.93
0.14
−13.08%
Follow PFSA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 9.69 | 10.12 | 11.15 | 10.55 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 10.16 | 11.16 | 13.00 | 41,250.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 2 | 2 | 2 | 2 | 2 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 0 | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | — | |||||
| EBT | — | — | — | — | — | 0 | 8 | 2 | (9) | (36) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (9,230.00) | 0.00 | |||||
| Net income | — | 0 | — | — | — | 0 | 7 | 1 | (9) | (36) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 333.33 | 0.00 | ||||
| Earnings | — | — | — | — | — | 434.30 | 10,375.97 | 1,474.80 | (35,500.00) | (10,701.00) | |||||
| Cash flow | — | — | — | — | — | (1,104.00) | (830.29) | (2,949.86) | (6,886.67) | (4,778.82) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (590.59) | |||||
| Free cash flow | — | — | — | — | — | (1,104.00) | (830.29) | (2,949.86) | (6,886.67) | (5,369.41) | |||||
| Book value | — | — | — | — | — | (9,848.67) | (885.00) | (4,941.86) | (397,350.00) | (7,840.59) | |||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (22.80) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (1) | (2) | (2) | (16) | ||||
| Capex | — | — | — | — | — | — | — | — | — | (2) | |||||
| Free cash flow | — | — | — | — | — | (1) | (1) | (2) | (2) | (18) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | 0 | (3) | (57) | (18) | ||||
| Total debt | — | — | — | — | — | — | — | — | 47 | 13 | |||||
| Net debt | — | — | — | — | — | (1) | 0 | 0 | 47 | 12 | |||||
| Shareholders’ equity | — | — | — | — | — | (6) | (1) | (3) | (119) | (27) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.16 | 3.70 | 1.13 | (132.26) | (1,046.23) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 0.33 | (219.58) | (56.97) | 15.05 | 49.12 | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2024
Charts ten years each
PROFUSA, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NUWE Nuwellis, Inc. | $2.0M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AFIB Acutus Medical, Inc. | $1.7M | — (loss-making) | — (loss-making) | +204.18% (above 0%: growing) | n/m | +76.40% (above 0%: growing) | 14.20% | (3.81%) | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | — (loss-making) | — | −30.67% (below 0%: shrinking) | n/m | −167.90% (below 0%: shrinking) | 50.33% | (33.62%) | Compare |
| DYNTQ Dynatronics Corporation | $1.2M | — (loss-making) | — (loss-making) | −7.61% (below 0%: shrinking) | n/m | −193.04% (below 0%: shrinking) | 24.65% | (1.26%) | Compare |
| THMO ThermoGenesis Holdings, Inc. | $1.1M | — (loss-making) | 5.5× | +6.42% (above 0%: growing) | n/m | +62.12% (above 0%: growing) | 43.92% | (20.35%) | Compare |
| SSKN Strata Skin Sciences, Inc. | $1.0M | — (loss-making) | — (loss-making) | −2.97% (below 0%: shrinking) | n/m | −376.88% (below 0%: shrinking) | 61.82% | 7.66% | Compare |
| FEED ENvue Medical, Inc. | $950.0K | — (loss-making) | — (loss-making) | −51.62% (below 0%: shrinking) | n/m | +19.75% (above 0%: growing) | (111.30%) | (2,290.38%) | Compare |
| PFSA PROFUSA, Inc. | $650.0K | 0.0× | — | — | n/m | −359.25% (below 0%: shrinking) | 100.00% | 0.00% | |
| MOTS Motus GI Holdings, Inc. | $420.0K | — (loss-making) | — (loss-making) | +14.29% (above 0%: growing) | n/m | +58.21% (above 0%: growing) | 81.25% | (3,165.63%) | Compare |
| Median of peers | $1.1M | — | — | +1.72% | — | −15.90% | 47.12% | (26.98%) |
PROFUSA, Inc. (PFSA) key facts
- PROFUSA, Inc. (PFSA) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- PROFUSA, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $100,000.00.
- As of October 16, 2026, PFSA traded at $0.93, a market capitalization of $650,000.00.
- Return on equity was 49.1% and debt-to-equity -0.19.
- Its Altman Z-score is −83.94 (distress zone) for fiscal 2024.